OncoMatch/Clinical Trials/NCT05289687
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Is NCT05289687 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Daratumumab / Hyaluronidase and Daratumumab / Hyaluronidase for t-cell acute lymphoblastic leukemia.
Treatment: Daratumumab / Hyaluronidase · Daratumumab / Hyaluronidase · Daratumumab / Hyaluronidase · Daratumumab / Hyaluronidase — In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: intensive chemotherapy
must be in first or later hematologic CR or CRi after a minimum of 2 blocks of intensive chemotherapy
Lab requirements
Blood counts
ANC ≥ 750/μL; Platelets ≥ 75,000/μL
Kidney function
Creatinine ≤ 1.5 x institutional ULN or Creatinine Clearance > 30 ml/min
Liver function
Total or Direct bilirubin ≤ 2 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3.0 × institutional ULN
Cardiac function
NYHA Functional Classification class 2B or better
Absolute neutrophil count (ANC) ≥ 750/μL; Platelets ≥ 75,000/μL; Total or Direct bilirubin ≤ 2 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3.0 × institutional ULN; Creatinine ≤ 1.5 x institutional ULN or Creatinine Clearance > 30 ml/min; ... cardiac disease ... NYHA Functional Classification class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwestern · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify